Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Health officials reported that cases of human metapneumovirus (HMPV) spiked this spring as COVID-19 and Respiratory Syncytial Virus cases fell. National data from the Centers for Disease Control ...

(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Study shows key role for human T cells in the control of Respiratory Syncytial Virus (RSV) infection. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2023 / 05 ...

HMPV is considered to be part of the Pneumoviridae viral family, which is the same group Respiratory Syncytial Virus (RSV) is associated with, a Johns Hopkins Center for Health Security report says.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

At the peak of the respiratory virus season, there could be between 15 and 25 new weekly hospitalizations for every 100,000 people in the US, according to the analysis.

Respiratory syncytial virus (RSV) is a highly contagious and seasonal respiratory virus that mainly causes common cold symptoms in healthy adults but can cause more serious lung infections in ...